Blueprint’s Ayvakit Mastocytosis Results Raise Commercial Uncertainty
The Phase III PIONEER study in indolent systemic mastocytosis met the primary endpoint, but the magnitude of benefit came up short of analysts’ expectations.
You may also be interested in...
The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.
CEO Fabrice Chouraqui spoke with Scrip about the company’s new $121m financing and its use of machine learning to target the whole cell instead of molecular targets in novel therapies.
Top-line Phase III results for Talzenna/Xtandi showed improved PFS in mCRPC patients regardless of HRR mutation status, where AstraZeneca/Merck have developed fellow PARP inhibitor Lynparza.